WC
SVA

Wexford Capital’s Sinovac Biotech, Ltd SVA Stock Holding History

Wexford Capital’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-56,000
Closed -$403K – 225
2014
Q1 		$403K Hold
56,000
– – 0.03% 154
2013
Q4 		$343K Buy
+56,000
New +$337K 0.03% 182

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wexford Capital's SVA Position: Q2 2014 in Review

Wexford Capital sold out of Sinovac Biotech, Ltd (SVA) in Q2 2014, closing a stake of 56,000 shares — an estimated $403K sold.

Wexford Capital first reported a position in SVA in Q4 2013 and held it in 2 quarters. The position peaked at $403K in Q1 2014. 50 funds tracked by Wall St. Rank hold SVA as of Q2 2014.

  • Wexford Capital reported no remaining Sinovac Biotech, Ltd position as of Q2 2014 after selling out during the quarter.
  • Wexford Capital sold 56,000 Sinovac Biotech, Ltd shares in Q2 2014, an estimated $403K.
  • Wexford Capital first reported a position in Sinovac Biotech, Ltd in Q4 2013 and held it in 2 quarters.
  • Wexford Capital's Sinovac Biotech, Ltd position peaked at $403K in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2014.

Based on Wexford Capital's 13F filing for Q2 2014, filed 13 Aug 2014.